ABSI Quote, Financials, Valuation and Earnings

NovaBay Pharmaceuticals has a net margin of -4358.35% compared to Absci's net margin of -49.65%. Absci's return on equity of -50.63% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Absci has a consensus price target of $9.13, signalling upside risk potential of 191.53%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 46.55%. Given that Absci has higher upside potential than NovaBay Pharmaceuticals, analysts believe Absci is more attractive than NovaBay Pharmaceuticals.

Absci has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.897, suggesting its less volatile than the S&P 500 by 10.271%.

Absci has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Absci pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Absci quarterly revenues are $665K, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Absci's net income of -$29M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Absci's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Absci is 76.09x versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -4358.35% compared to Absci's net margin of --. Absci's return on equity of -50.63% beat Palatin Technologies's return on equity of --.

Absci has a consensus price target of $9.13, signalling upside risk potential of 191.53%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 3281.64%. Given that Palatin Technologies has higher upside potential than Absci, analysts believe Palatin Technologies is more attractive than Absci.

Absci has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.896, suggesting its less volatile than the S&P 500 by 10.45%.

Absci has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Absci pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Absci quarterly revenues are $665K, which are larger than Palatin Technologies quarterly revenues of --. Absci's net income of -$29M is higher than Palatin Technologies's net income of --. Notably, Absci's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Absci is 76.09x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Recursion Pharmaceuticals has a net margin of -4358.35% compared to Absci's net margin of -3965.99%. Absci's return on equity of -50.63% beat Recursion Pharmaceuticals's return on equity of -77.06%.

Absci has a consensus price target of $9.13, signalling upside risk potential of 191.53%. On the other hand Recursion Pharmaceuticals has an analysts' consensus of $8.71 which suggests that it could grow by 52.08%. Given that Absci has higher upside potential than Recursion Pharmaceuticals, analysts believe Absci is more attractive than Recursion Pharmaceuticals.

Absci has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Recursion Pharmaceuticals has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Absci has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Recursion Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Absci pays -- of its earnings as a dividend. Recursion Pharmaceuticals pays out -- of its earnings as a dividend.

Absci quarterly revenues are $665K, which are smaller than Recursion Pharmaceuticals quarterly revenues of $4.5M. Absci's net income of -$29M is higher than Recursion Pharmaceuticals's net income of -$178.9M. Notably, Absci's price-to-earnings ratio is -- while Recursion Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Absci is 76.09x versus 26.88x for Recursion Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of -4358.35% compared to Absci's net margin of --. Absci's return on equity of -50.63% beat Theriva Biologics's return on equity of --.

Absci has a consensus price target of $9.13, signalling upside risk potential of 191.53%. On the other hand Theriva Biologics has an analysts' consensus of $6.00 which suggests that it could grow by 322.27%. Given that Theriva Biologics has higher upside potential than Absci, analysts believe Theriva Biologics is more attractive than Absci.

Absci has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.169, suggesting its more volatile than the S&P 500 by 16.92%.

Absci has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Absci pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

Absci quarterly revenues are $665K, which are larger than Theriva Biologics quarterly revenues of --. Absci's net income of -$29M is lower than Theriva Biologics's net income of -$4.4M. Notably, Absci's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Absci is 76.09x versus 0.63x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.